Hypertension

AstraZeneca will share the positive topline 24-hour BP monitoring data with global regulatory authorities and present findings at the 2025 AHA Scientific Sessions.

Your daily dose of the clinical news you may have missed.

Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.

Analysis presented at AHA Hypertension 2025 showed fewer than 6% of US adults use salt substitutes, despite their potential to improve BP control.

Caissa Troutman, member of the Obesity Medicine Association, emphasizes the importance of shared decision-making in overcoming barriers.

Your daily dose of the clinical news you may have missed.

Updates to the 2017 guideline focus on new monitoring strategies, earlier intervention to reduce cognitive decline, improved perinatal care, and refined risk assessment.

Adequate sleep tops the 4 elements most important to CV health after menopause, with blood pressure, glucose levels, and smoking status close behind.

Your daily dose of the clinical news you may have missed.

ENDO 2025: The publications reflect growing consensus that integration of endocrine screening into standard clinical workflows is essential for early risk detection and long-term disease prevention.

Baxdrostat met the primary and all secondary endpoints, setting up a first regulatory filing for the selective aldosterone synthase inhibitor, according to AstraZeneca.

These new FDA-approved drugs include treatments for migraine, chronic spontaneous urticaria, RSV, and more.

Your daily dose of the clinical news you may have missed.

For individuals with T2D, findings are more than numeric; a 5-mm Hg reduction in SBP reduces stroke risk by 14%, CV events by 6%, and heart failure by 8%, authors wrote.

The novel triple fixed-dose combination of telmisartan, amlodipine and indapamide, is the first of its kind approved for initial treatment of hypertension.

Adults with both HTN and T2D had more than twice the risk of all-cause mortality and nearly three times the risk of cardiovascular mortality, according to new data.

Low-dose clorthalidone offers clinicians a new option for initiating treatment that may mitigate well-known metabolic adverse effects.

An EHR advisory that combined alerts to medical assistants with escalation to clinicians increased likelihood of hypertension control by a mean 18% per month.

Aprocitentan, when added to background therapy of at least 3 antihypertensive agents, led to clinically meaningful and sustained BP reduction in this preplanned subanalysis.

Your daily dose of the clinical news you may have missed.

Close monitoring for dnPPHTN during the first 2 weeks post-delivery is highly recommended for women determined to be at high risk for the hypertensive disorder of pregnancy.

Cardiovascular disease is still the leading cause of death in the US, driven by rising rates of obesity, diabetes, and hypertension, according to new report.

Caissa Troutman, MD, shares 3 key strategies for managing hypertension in patients with obesity in primary care.

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

Caissa Troutman, MD, stresses the importance of building trust with patients through active listening and consistent, non-judgmental communication.

Obesity medicine expert Caissa Troutman, MD, suggests using annual physicals as a "gateway" to identify patients with obesity with elevated blood pressure.

Caissa Troutman, MD, provides an overview of the connection between obesity and hypertension.

Caissa Troutman, MD, an obesity medicine and family medicine physician, emphasizes early treatment of obesity, along with HTN management, can improve patient outcomes.

Your daily dose of the clinical news you may have missed.

People with hypertension who adhered to the mobile app demonstrated well-controlled blood pressure over a 12-week observational period.